Kevin Kunzmann

Articles

COVID-19 Pill Molnupiravir Gets EUA Approval by FDA

December 23, 2021

In the space of 2 days, the FDA approved at-home oral treatments for patients with mild-to-moderate COVID-19, drug that were months in development. Today, it was Merck and Ridgeback Biotherapeutics’ turn.

Moderna Praises Its COVID-19 Child Vaccine Data

October 25, 2021

Moderna’s phase 2/3 pediatric trial showed a lesser dose of the company’s 2-dose COVID-19 vaccine mRNA-1273 is associated with a significant neutralizing antibody response in children aged 6 to

Johnson & Johnson Touts COVID-19 Vaccine Booster Shot

September 21, 2021

Investigators concluded that their data demonstrate the “high and stable effectiveness” of the single-dose COVID-19 vaccine across both high-risk patient subpopulations, as well as residents in areas more adversely affected by the delta variant.

FDA Grants Full Approval to Pfizer/BioNTech Vaccine

August 23, 2021

Health care experts hope that the move will induce the vaccine hesitant—in the public, and among health care professionals—to get inoculated in the hope that that will stem the rising tide of the delta variant.